Full-Time

Financial Planning & Analysis Director

Financial Planning & Analysis

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

Bachelor's

Category
Finance & Banking (1)
Required Skills
Forecasting
Financial analysis
Excel/Numbers/Sheets

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • Bachelor's degree in Accounting, Finance, Business Administration, or a related field, or equivalent combination of education and relevant professional experience.
  • 10+ years of progressive FP&A, corporate finance, or strategic finance experience, preferably within biotechnology, pharmaceutical, or life sciences organizations.
  • Experience building and maintaining complex financial models, including long-range planning, scenario analysis, and cash forecasting.
  • Experience in biotech operating models, including preclinical and clinical development timelines, R&D investment drivers, and program-level financial planning.
  • Experience preparing executive-level presentations and communicating complex financial concepts clearly.
  • Experience with advanced Excel modeling skills and financial planning tools
  • Experience identifying business drivers, trends, and opportunities.
Responsibilities
  • Build and maintain comprehensive financial models incorporating clinical development timelines, program costs, operating assumptions, and strategic scenarios.
  • Develop long-range financial plans and forecasts that support business objectives and capital allocation decisions.
  • Analyze program-level investment requirements, clinical development costs, and resource needs across the pipeline.
  • Develop scenario analyses to evaluate strategic alternatives, including clinical development strategies, partnership opportunities, and other business initiatives.
  • Provide insights into cash runway, capital requirements, and financial trade-offs.
  • Lead the annual budgeting process and ongoing forecasting cycles, including quarterly updates and long-range planning.
  • Partner with functional leaders across R&D, Clinical Operations, and Corporate Operations to develop realistic financial plans aligned with business priorities.
  • Analyze actual results against budget and forecast, identifying trends, risks, opportunities, and recommended actions.
  • Establish meaningful financial and operational metrics to measure business performance and support decision-making.
  • Develop processes to improve financial visibility and accountability across the organization.
  • Prepare executive-level financial analyses, presentations, and insights for senior leadership and Board discussions.
  • Translate complex financial, operational, and clinical information into clear recommendations for decision-makers.
  • Support investor-facing analyses, diligence requests, and strategic financial materials.
  • Develop reporting frameworks that highlight key business drivers, capital efficiency, and pipeline progress.
  • Serve as a trusted finance partner to scientific and operational leaders by developing strong relationships, understanding their goals and challenges, and providing thoughtful financial guidance that enables teams to focus on advancing our science. Act as an educator and translator, simplifying financial concepts and removing administrative burdens while ensuring teams have the information needed to make effective business decisions.
  • Partner with Accounting to ensure accurate financial reporting, forecasting inputs, and alignment between actual results and financial models.
  • Develop scalable FP&A processes, tools, and reporting infrastructure to support company growth.
  • Support implementation and optimization of financial systems and planning tools.
  • Build program-level financial tracking methodologies to improve visibility into clinical development investments.
  • Build and develop FP&A capabilities as the organization grows.
  • Mentor and coach finance team members in financial modeling, forecasting, and business partnership.
  • Establish best practices for financial analysis, reporting, and strategic planning.
Desired Qualifications
  • Master's degree in Business Administration (MBA), Finance, Accounting, or a related field, or equivalent combination of education and relevant professional experience.
  • Experience in a clinical-stage biotech or pharmaceutical company.
  • Experience supporting company growth, financing activities, or strategic transactions.
  • Experience implementing or enhancing FP&A systems (Adaptive Planning, Anaplan, NetSuite Planning & Budgeting, or similar).
  • Familiarity with ERP systems such as NetSuite, Sage Intacct, or similar platforms.
  • Experience developing Board-level financial materials.
  • Experience with equity compensation modeling and workforce planning.
  • Exposure to public company reporting requirements and SEC processes.
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding